Group One Trading’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $369K | Sell |
2,800
-1,200
| -30% | -$159K | ﹤0.01% | 3613 |
|
|
2025
Q4 | $567K | Buy |
4,000
+3,900
| +3,900% | +$565K | ﹤0.01% | 3384 |
|
|
2025
Q3 | $14K | Sell |
100
-1,300
| -93% | -$176K | ﹤0.01% | 6956 |
|
|
2025
Q2 | $176K | Sell |
1,400
-3,100
| -69% | -$356K | ﹤0.01% | 4467 |
|
|
2025
Q1 | $498K | Buy |
+4,500
| New | +$570K | ﹤0.01% | 3087 |
|
|
2024
Q4 | – | Sell |
-11,300
| Closed | -$1.3M | – | 7721 |
|
|
2024
Q3 | $1.3M | Sell |
11,300
-5,600
| -33% | -$768K | ﹤0.01% | 2089 |
|
|
2024
Q2 | $2.33M | Buy |
16,900
+6,500
| +63% | +$891K | 0.01% | 1321 |
|
|
2024
Q1 | $1.43M | Buy |
10,400
+400
| +4% | +$54.6K | 0.01% | 1770 |
|
|
2023
Q4 | $1.32M | Sell |
10,000
-1,000
| -9% | -$115K | ﹤0.01% | 2206 |
|
|
2023
Q3 | $1.24M | Buy |
11,000
+7,100
| +182% | +$748K | ﹤0.01% | 2060 |
|
|
2023
Q2 | $368K | Sell |
3,900
-18,800
| -83% | -$1.84M | ﹤0.01% | 3339 |
|
|
2023
Q1 | $2.3M | Buy |
+22,700
| New | +$2.36M | 0.01% | 1416 |
|
|
2022
Q4 | – | Sell |
-25,800
| Closed | -$2.74M | – | 7801 |
|
|
2022
Q3 | $2.74M | Sell |
25,800
-12,400
| -32% | -$1.26M | 0.01% | 1638 |
|
|
2022
Q2 | $3.72M | Sell |
38,200
-62,300
| -62% | -$5.75M | 0.01% | 1518 |
|
|
2022
Q1 | $9.42M | Buy |
100,500
+76,900
| +326% | +$6.52M | 0.01% | 1046 |
|
|
2021
Q4 | $2.01M | Buy |
23,600
+18,400
| +354% | +$1.69M | ﹤0.01% | 2592 |
|
|
2021
Q3 | $499K | Sell |
5,200
-16,600
| -76% | -$1.57M | ﹤0.01% | 4189 |
|
|
2021
Q2 | $2.12M | Buy |
21,800
+15,600
| +252% | +$1.5M | ﹤0.01% | 2582 |
|
|
2021
Q1 | $603K | Sell |
6,200
-31,500
| -84% | -$3.3M | ﹤0.01% | 3807 |
|
|
2020
Q4 | $3.61M | Buy |
37,700
+28,800
| +324% | +$2.78M | 0.01% | 1545 |
|
|
2020
Q3 | $856K | Buy |
8,900
+200
| +2% | +$23.1K | ﹤0.01% | 2340 |
|
|
2020
Q2 | $1.06M | Sell |
8,700
-1,400
| -14% | -$155K | ﹤0.01% | 1967 |
|
|
2020
Q1 | $874K | Sell |
10,100
-41,000
| -80% | -$4.01M | 0.01% | 1623 |
|
|
2019
Q4 | $5.49M | Buy |
51,100
+32,700
| +178% | +$3.42M | 0.04% | 627 |
|
|
2019
Q3 | $1.66M | Buy |
18,400
+11,200
| +156% | +$1.05M | 0.01% | 1352 |
|
|
2019
Q2 | $608K | Buy |
7,200
+4,300
| +148% | +$353K | 0.01% | 1963 |
|
|
2019
Q1 | $255K | Sell |
2,900
-3,700
| -56% | -$309K | ﹤0.01% | 2521 |
|
|
2018
Q4 | $471K | Buy |
6,600
+3,600
| +120% | +$345K | ﹤0.01% | 2022 |
|
|
2018
Q3 | $369K | Sell |
3,000
-25,800
| -90% | -$2.93M | ﹤0.01% | 2536 |
|
|
2018
Q2 | $2.83M | Buy |
28,800
+3,400
| +13% | +$304K | 0.02% | 877 |
|
|
2018
Q1 | $2.11M | Sell |
25,400
-27,600
| -52% | -$2.33M | 0.02% | 974 |
|
|
2017
Q4 | $4.11M | Buy |
53,000
+51,600
| +3,686% | +$3.52M | 0.03% | 746 |
|
|
2017
Q3 | $86K | Sell |
1,400
-6,800
| -83% | -$359K | ﹤0.01% | 3327 |
|
|
2017
Q2 | $377K | Sell |
8,200
-2,300
| -22% | -$112K | ﹤0.01% | 2182 |
|
|
2017
Q1 | $455K | Sell |
10,500
-45,800
| -81% | -$1.96M | 0.01% | 1907 |
|
|
2016
Q4 | $2.18M | Buy |
56,300
+21,900
| +64% | +$991K | 0.02% | 873 |
|
|
2016
Q3 | $1.74M | Sell |
34,400
-300
| -0.9% | -$14.9K | 0.02% | 923 |
|
|
2016
Q2 | $1.58M | Buy |
34,700
+3,300
| +11% | +$152K | 0.02% | 952 |
|
|
2016
Q1 | $1.24M | Sell |
31,400
-29,200
| -48% | -$1.16M | 0.02% | 1030 |
|
|
2015
Q4 | $3.43M | Sell |
60,600
-31,000
| -34% | -$1.58M | 0.04% | 549 |
|
|
2015
Q3 | $3.65M | Buy |
91,600
+42,700
| +87% | +$2.06M | 0.05% | 472 |
|
|
2015
Q2 | $2.33M | Sell |
48,900
-39,800
| -45% | -$1.69M | 0.03% | 655 |
|
|
2015
Q1 | $3.52M | Sell |
88,700
-40,200
| -31% | -$1.44M | 0.06% | 376 |
|
|
2014
Q4 | $2.88M | Buy |
128,900
+67,400
| +110% | +$1.28M | 0.04% | 472 |
|
|
2014
Q3 | $964K | Buy |
61,500
+13,800
| +29% | +$206K | 0.01% | 1132 |
|
|
2014
Q2 | $708K | Buy |
47,700
+35,100
| +279% | +$495K | 0.01% | 1377 |
|
|
2014
Q1 | $203K | Sell |
12,600
-6,600
| -34% | -$113K | ﹤0.01% | 2432 |
|
|
2013
Q4 | $179K | Sell |
19,200
-94,300
| -83% | -$920K | ﹤0.01% | 2538 |
|
|
2013
Q3 | $1.28M | Buy |
113,500
+79,500
| +234% | +$1.09M | 0.02% | 826 |
|
|
2013
Q2 | $455K | Buy |
+34,000
| New | +$418K | 0.01% | 1432 |
|
Other funds holding NBIX
VPM
VCM
Group One Trading's NBIX Position: Q1 2026 in Review
Group One Trading reduced its Neurocrine Biosciences (NBIX) stake by 24% in Q1 2026, selling an estimated $41.9K and leaving 1,014 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #4463.
Group One Trading first reported a position in NBIX in Q2 2013 and has held it in 26 quarters since. The position peaked at $4.83M in Q1 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Group One Trading held 1,014 shares of Neurocrine Biosciences worth $134K as of Q1 2026.
- Group One Trading sold 316 Neurocrine Biosciences shares in Q1 2026, an estimated $41.9K.
- Neurocrine Biosciences made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4463 holding.
- Group One Trading first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 26 quarters since.
- Group One Trading's Neurocrine Biosciences position peaked at $4.83M in Q1 2022.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.